Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission

International Journal of Hematology

Volumn 81, Issue 3, 2005, Pages 258-263

  Lee, Jeeyun ^a   Lee, Mark H ^b   Park, Keon Woo ^a   Kang, Jung Hoon ^a   Im, Do Hyung ^a   Kim, Kihyun ^a   Lee, Se Hoon ^a   Kim, Won Seog ^a   Park, Jinny ^a   Jung, Chul Won ^a   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Autologous transplant; First remission; PBSCT

Indexed keywords

BUSULFAN; CARBOPLATIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL COUNT; CELL NUCLEUS; CELL SUBPOPULATION; CLINICAL ARTICLE; COLONY FORMING UNIT GM; CONSOLIDATION CHEMOTHERAPY; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; NEUTROPHIL; NUCLEATED CELL; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL MOBILIZATION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STEM CELL MOBILIZATION; THERAPY DELAY; THROMBOCYTE; TIME; AUTOTRANSPLANTATION; CLINICAL TRIAL; GRAFT SURVIVAL; LEUKAPHERESIS; MIDDLE AGED; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKAPHERESIS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 20344375467     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.A30411     Document Type: Article

References (25)

1. Lowenberg B, Verdonck LJ, Dekker AW, et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J Clin Oncol. 1990;8: 287-294.
2. Sierra J, Brunet S, Granena A, et al. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia: Catalan Group for Bone Marrow Transplantation. J Clin Oncol. 1996;14: 1353-1363.
3. Cassileth PA, Andersen J, Lazarus HM, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol. 1993;11:314-319.
4. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia: European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995; 332:217-223.
5. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial: UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet. 1998;351:700-708.
6. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-1656.
7. Martin C, Torres A, Leon A, et al. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission: role of intensification therapy in outcome. Bone Marrow Transplant. 1998;21:375-382.
8. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547-2555.
9. Watts MJ, Sullivan AM, Jamieson E, et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predictive for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol. 1997;15:535-546.
10. Moskowitz CH, Glassman JR, Wuest D, et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res. 1998;4:311-316.
11. Sautois B, Fraipont V, Baudoux E, et al. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Haematologica. 1999;84:342-349.
12. Lee JL, Kim SB, Lee GW, et al. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields. Transfus Apheresis Sci. 2003;29:29-37.
13. Jowitt SN, Chang J, Morgenstern GR, et al. Factors which affect the CFU-GM content of the peripheral blood haemopoietic progenitor cell harvests in patients with acute myeloid leukaemia. Br J Haematol. 1998;100:688-694.
14. Carral A, de la Rubia J, Martin G, et al. Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. Leuk Res. 2003;27:5-12.
15. Stewart DA, Guo D, Morris D, et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant. 1999;23:111-117.
16. Park J, Lee MH, Lee HR, et al. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia. Bone Marrow Transplant. 2003: 32:889-895.
17. Carlo-Stella C, Tabilio A, Regazzi E, et al. Effects of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors. Bone Marrow Transplant. 1997;20:465-471.
18. Pettengell R, Morgenstern GR, Woll PJ, et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood. 1993;82:3770-3777.
19. Woo HY, Kim HR, Seong KW, Lee HK, Oh WI, Kim DW. Correlation between progenitor cell dose and the rate of engraftment in autologous peripheral blood stem cell transplantation and allogeneic bone marrow transplantation [in Korean]. Korean J Blood Transfus. 2000;11:35-47.
20. Teshima T, Harada M, Takamatsu Y, et al. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant. 1992;10: 215-220.
21. Reid CD, Kirk A, Muir J, Chanarin I. The recovery of circulating progenitor cells after chemotherapy in AML and ALL and its relation to the rate of bone marrow regeneration after aplasia. Br J Haematol. 1989;72:21-27.
22. Voog E, Le QH, Philip I, et al. Autologous transplantation in acute myeloid leukemia: peripheral blood stem cell harvest after mobilization in steady state by granulocyte colony-stimulating factor alone. Ann Hematol. 2001;80:584-591.
23. Kim JH, Min WS, Eom KS, et al. Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission. Bone Marrow Transplant. 2004;34:215-220.
24. Keating S, Suciu S, de Witte T, et al. The stem cell mobilization capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia. 2003;17:60-67.
25. Feller N, Schuurhuis GJ, van der Pol MA, et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroups of patients with poor clinical outcome. Leukemia. 2003;17:68-75.